Elidel® (pimecrolimus) Cream 1%
  Novartis Pharma US

 

If you don't have prescription coverage and can't afford your medicines, visit: www.pap.novartis.com or call 1-800-245-5356 


FDA Public Health Advisory

Updated Prescribing Information


You may or may not be aware that the Food and Drug Administration (FDA) on January 19, 2006, approved an updated label (prescribing information) to include a boxed warning and medication guide.

As a result, you may have some questions for your doctor about ELIDEL. Below, you will find some additional information about ELIDEL's label change. If you have any further questions about this issue, please speak with your doctor.

Questions Regarding ELIDEL's Label Change
Information Regarding ELIDEL
Additional Resources About Eczema

Questions Regarding ELIDEL's Label Change




What does the boxed warning in the ELIDEL label say? What are the other changes to the label for ELIDEL?
The boxed warning, which is located in the Warning section of the product label, states:

Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established

Although a causal relationship has not been established, rare cases of malignancy (e.g. skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including ELIDEL Cream.
Therefore:

Continuous long-term use of topical calcineurin inhibitors, including ELIDEL Cream, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.
ELIDEL Cream is not indicated for use in children less than 2 years of age.

Changes were also made to other sections of the label, including the wording of the indication as well as the addition of a Warning's section.

What is a boxed (or "black box") warning?
A boxed warning is included in a product label. It is used when the FDA believes there is a need to highlight a significant safety concern.

What does the medication guide for ELIDEL say?
The medication guide is based on the updated label and includes important information you should know about ELIDEL, how you should use ELIDEL, what you should avoid when using ELIDEL, and more.

Click here to view the entire medication guide for ELIDEL.

What is a medication guide?
A medication guide is issued by the FDA and includes patient information for prescription drugs when the FDA believes they pose a serious and significant public health concern.

Why did the FDA require a label change in January 2006?
The FDA changed the label due to concerns over a specific class of drugs that treat eczema, called topical calcineurin inhibitors, including ELIDEL.

The FDA's concern for these types of drugs was based on a theoretical risk which stemmed from events that have been seen with high doses in animal studies and transplant patients. The adverse events were associated with prolonged
systemic immunosuppression.

This effect cannot be achieved with ELIDEL Cream because it is applied to the skin and very low amounts enter the blood stream. In fact, in clinical studies most blood levels of ELIDEL were too low to measure.

What does systemic immunosuppression mean?
Systemic immunosuppression is a disorder or condition when the immune system is not able to perform its routine function. The immune system helps protect the body from diseases and infections, for example identifying and attacking foreign antigens. Systemic immunosuppression can be the result of many different causes or factors (such as genetic conditions, and some disease states or treatments).

Is there any evidence linking ELIDEL Cream to the cause of malignancy or lymphoma?
There is no evidence of a cause and effect relationship between the use of ELIDEL Cream and malignancy or lymphoma. This is acknowledged in the FDA revised label.

Is ELIDEL Cream safe for the use in children?
Yes. ELIDEL Cream is approved by the FDA for use in people ages 2 and older.
Back to Top

Information Regarding Elidel



ELIDEL Cream has been shown in human clinical trials to be a safe and effective treatment option for patients 2 years and older with mild to moderate atopic dermatitis (eczema). ELIDEL is an important treatment option when other treatments don't work, or when their use is not advisable. As with all medications, we recommend that patients and caregivers discuss treatment options with their doctor or healthcare provider to determine if ELIDEL is right for them.

Because ELIDEL Cream is applied to the skin, very low amounts enter the blood stream. In clinical studies most blood levels of ELIDEL were too low to measure.

If you have further questions or concerns, please talk with your doctor.
Back to Top

Additional Resources About Eczema



National Eczema Association
http://www.nationaleczema.org
The National Eczema Association (NEA) works to improve the health and the quality of life of persons living with atopic dermatitis/eczema, including those who have the disease as well as their loved ones.

Inflammatory Skin Disease Institute
www.isdionline.org
The goal of the Inflammatory Skin Disease Institute (ISDI) is to promote public awareness and enhanced treatment of inflammatory skin diseases through education, research, and patient advocacy.

To contact our Customer Interaction Center please dial
888-NOW-NOVA (888-669-6682) Monday - Friday, 8:30am - 5:00pm EST
Back to Top


Prescribing information
ELIDEL Home  |  Treating with ELIDEL  |  Managing Eczema
Diagnosing Eczema  |  Eczema FAQs
Understanding Eczema (Atopic Dermatitis)
Updated Prescribing Information  |  Patient Medication Guide
Important Safety Information  |  Healthcare Professionals

Contact Us  |  Site Guide  |  Site Map

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ©2010
Novartis Pharmaceuticals Corporation. All rights reserved.